Related Experiment Video
Updated: Jan 31, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer
Elisabetta Pietri1, Ilaria Massa2, Sara Bravaccini3
1Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Lessons Learned:
The androgen receptor (AR) is present in most breast cancers (BC), but its exploitation as a therapeutic target has been limited.This study explored the activity of dehydroepiandrosterone (DHEA), a precursor being transformed into androgens within BC cells, in combination with an aromatase inhibitor (to block DHEA conversion into estrogens), in a two-stage phase II study in patients with AR-positive/estrogen receptor-positive/human epidermal growth receptor 2-negative metastatic BC.Although well tolerated, only 1 of 12 patients obtained a prolonged clinical benefit, and the study was closed after its first stage for poor activity.
Background:
Androgen receptors (AR) are expressed in most breast cancers, and AR-agonists have some activity in these neoplasms. We investigated the safety and activity of the androgen precursor dehydroepiandrosterone (DHEA) in combination with an aromatase inhibitor (AI) in patients with AR-positive metastatic breast cancer (MBC).
Methods:
A two-stage phase II study was conducted in two patient cohorts, one with estrogen receptor (ER)-positive (resistant to AIs) and the other with triple-negative MBC. DHEA 100 mg/day was administered orally. The combination with an AI aimed to prevent the conversion of DHEA into estrogens. The main endpoint was the clinical benefit rate. The triple-negative cohort was closed early.
Results:
Twelve patients with ER-positive MBC were enrolled. DHEA-related adverse events, reported in four patients, included grade 2 fatigue, erythema, and transaminitis, and grade 1 drowsiness and musculoskeletal pain. Clinical benefit was observed in one patient with ER-positive disease whose tumor had AR gene amplification. There was wide inter- and intra-patient variation in serum levels of DHEA and its metabolites.
Conclusion:
DHEA showed excellent safety but poor activity in MBC. Although dose and patient selection could be improved, high serum level variability may hamper further DHEA development in this setting.
Insights
Dehydroepiandrosterone (DHEA) combined with aromatase inhibitors showed good safety but limited effectiveness in treating metastatic breast cancer. High variability in DHEA levels may hinder its future development for this condition.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Androgen receptors (AR) are prevalent in breast cancer (BC), yet therapeutic targeting remains challenging.
- AR-agonists demonstrate some efficacy in BC treatment.
- Dehydroepiandrosterone (DHEA), an androgen precursor, was investigated for its potential in AR-positive metastatic breast cancer (MBC).
Purpose of the Study:
- To evaluate the safety and activity of DHEA in combination with an aromatase inhibitor (AI) for AR-positive MBC.
- To assess the clinical benefit rate in patients with estrogen receptor (ER)-positive and triple-negative MBC.
- To explore the role of DHEA as a therapeutic agent in advanced breast cancer.
Main Methods:
- A two-stage phase II clinical study was conducted.
- Patients received oral DHEA (100 mg/day) along with an AI to inhibit estrogen conversion.
- Two cohorts were enrolled: ER-positive (AI-resistant) and triple-negative MBC; the triple-negative cohort was terminated early.
Main Results:
- Twelve patients with ER-positive MBC were enrolled; DHEA was well-tolerated with manageable adverse events.
- One patient with ER-positive disease and AR gene amplification achieved clinical benefit.
- Significant inter- and intra-patient variability in serum DHEA and metabolite levels was observed.
Conclusions:
- DHEA demonstrated excellent safety but poor clinical activity in metastatic breast cancer.
- While dose optimization and patient selection might be considered, the high variability in serum DHEA levels presents a significant challenge for its further development in this context.
- The study suggests limited efficacy of the DHEA and AI combination in AR-positive MBC.
More Related Videos
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
06:52Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence
Published on: November 5, 2021
Related Concept Videos
Internal Receptors
Phase Diagrams
Phase Transitions
Positive Regulator Molecules
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Position-effect Variegation